PMID- 35872781
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220726
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - The Changing Landscape of Anticoagulation in Pediatric Extracorporeal Membrane 
      Oxygenation: Use of the Direct Thrombin Inhibitors.
PG  - 887199
LID - 10.3389/fmed.2022.887199 [doi]
LID - 887199
AB  - Bleeding and thrombosis frequently occur in pediatric patients with 
      extracorporeal membrane oxygenation (ECMO) therapy. Until now, most patients are 
      anticoagulated with unfractionated heparin (UFH). However, heparin has many 
      disadvantages, such as binding to other plasma proteins and endothelial cells in 
      addition to antithrombin, causing an unpredictable response, challenging 
      monitoring, development of heparin resistance, and risk of heparin-induced 
      thrombocytopenia (HIT). Direct thrombin inhibitors (DTIs), such as bivalirudin 
      and argatroban, might be a good alternative. This review will discuss the use of 
      both UFH and DTIs in pediatric patients with ECMO therapy.
CI  - Copyright (c) 2022 Neunert, Chitlur and van Ommen.
FAU - Neunert, Cindy
AU  - Neunert C
AD  - Department of Pediatrics, Columbia University Medical Center, New York, NY, 
      United States.
FAU - Chitlur, Meera
AU  - Chitlur M
AD  - Division of Hematology, Oncology, Carmen and Ann Adams Department of Pediatrics, 
      Children's Hospital of Michigan, Central Michigan University, Detroit, MI, United 
      States.
FAU - van Ommen, Cornelia Heleen
AU  - van Ommen CH
AD  - Department of Pediatric Hematology and Oncology, Erasmus Medical Center 
      University Medical Center Sophia Children's Hospital, Rotterdam, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220706
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9299072
OTO - NOTNLM
OT  - anticoagulation
OT  - argatroban
OT  - bivalirudin
OT  - extracorporeal membrane oxygenation
OT  - pediatric
OT  - unfractionated heparin
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/26 06:00
MHDA- 2022/07/26 06:01
PMCR- 2022/07/06
CRDT- 2022/07/25 03:25
PHST- 2022/03/01 00:00 [received]
PHST- 2022/06/10 00:00 [accepted]
PHST- 2022/07/25 03:25 [entrez]
PHST- 2022/07/26 06:00 [pubmed]
PHST- 2022/07/26 06:01 [medline]
PHST- 2022/07/06 00:00 [pmc-release]
AID - 10.3389/fmed.2022.887199 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Jul 6;9:887199. doi: 10.3389/fmed.2022.887199. 
      eCollection 2022.